{
  "column-order": [
    "Ampicillin",
    "Pip-Tazo",
    "Cefazolin/ cephalexin",
    "Ceftriaxone",
    "Cefepime",
    "Gentamicin",
    "Ciprofloxacin (Levofloxacin)",
    "TMP-SMX",
    "Nitrofurantoin",
    "Vancomycin"
  ],
  "row-order": [
    "Citrobacter freundii",
    "Citrobacter koseri",
    "Enterobacter (Klebsiella) aerogenes",
    "Enterobacter cloacae",
    "Escherichia coli",
    "Klebsiella oxytoca",
    "Klebsiella pneumoniae",
    "Proteus mirabilis",
    "Pseudomonas aeruginosa",
    "Serratia marcescens",
    "Coagulase negative Staphylococcus",
    "Enterococcus spp.",
    "Staphylococcus aureus"
  ],
  "resistance-rates": [
    { "label": "ESBL", "year": 2021, "value": "3.9%" },
    { "label": "VRE", "year": 2021, "value": "19%" },
    { "label": "VRE", "year": 2019, "value": "25%" },
    { "label": "VRE", "year": 2018, "value": "32%" },
    { "label": "MRSA", "year": 2021, "value": "39%" },
    { "label": "MRSA", "year": 2019, "value": "51%" },
    { "label": "MRSA", "year": 2018, "value": "42%" }
  ],
  "footnotes": [
    "Organisms with less than 30 isolates are excluded due to small sample size",
    "CLSI breakpoints for pip/tazo and cefepime applied to Pseudomonas spp.",
    "Enterobacter, Citrobacter freundii, and Serratia may develop resistance during prolonged therapy with 3rd-generation cephalosporins as a result of derepression of AmpC B-lactamase. Therefore, isolates that are initially susceptible may become resistant within 3 to 4 days after start of therapy.",
    "Levofloxacin susceptibilty not published, however Ciprofloxacin traditionally closely predicts levofloxacin activity for Pseudomonas",
    "R = Intrinsic (i.e. not acquired) resistance. All wild-type isolates are expected to display resistance"
  ]
}
